SERUM PSEUDOURIDINE AS A BIOCHEMICAL MARKER IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA
SERUM PSEUDOURIDINE AS A BIOCHEMICAL MARKER IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA
复制标题
DOI：
10.1016/0009-8981(88)90221-5
复制
发表时间：
1988-12-15
影响因子：
5
通讯作者：
HIGASHINO, K
中科院分区：
文献类型：
--
作者：
AMURO, Y;NAKAOKA, H;HIGASHINO, K
采用高效液相色谱法测定肝细胞癌、肝硬化、其他良性肝胆疾病患者和健康对照者血清中假尿苷（转移核糖核酸的降解产物）的浓度。肝细胞癌患者血清假尿苷浓度显着高于肝硬化患者或对照组。 52 名肝细胞癌患者中，有 27 名 (51.9%) 的血清假尿苷浓度高于健康对照的平均值加上 2 个标准差。 36 名血清甲胎蛋白水平低于 400 ng/ml 的患者中有 14 名血清假尿苷浓度升高。总共，52 名患者中的 36 名患者 (69.2%) 可以通过这两种标记物的组合进行检测。两名在肝硬化过程中患上肝细胞癌且甲胎蛋白持续阴性的患者，在发生肝细胞癌时假性尿苷浓度较高。此外，7 名患有非常小癌症且甲胎蛋白呈阴性的患者中，有 4 名患者的血清假尿苷浓度升高。这些结果表明，血清假尿苷是一种有用的生化标志物，并且血清假尿苷和甲胎蛋白的组合被认为可以作为诊断肝细胞癌的互补标志物。
The concentration of serum pseudouridine, a degradation product of transfer ribonucleic acid, was determined by high-performance liquid chromatography in patients with hepatocellular carcinoma, liver cirrhosis, other benign hepatobiliary diseases, and healthy controls. The serum pseudouridine concentration in patients with hepatocellular carcinoma was significantly higher than that in patients with cirrhosis or the controls. Twenty-seven (51.9%) of 52 patients with hepatocellular carcinoma had serum pseudouridine concentrations higher than the mean value for healthy controls plus 2 SD. Fourteen of the 36 patients who had serum alphafetoprotein levels below 400 ng/ml, had elevated serum pseudouridine concentration. In total, 36 of the 52 patients (69.2%) could be detected by combination of these two markers. Two patients who had developed hepatocellular carcinoma during the course of cirrhosis and were continuously negative for alpha-fetoprotein, had higher levels of the pseudouridine concentration when hepatocellular carcinoma occurred. Furthermore, 4 of the 7 patients who had a very small cancer and were negative for alpha-fetoprotein, had elevated serum pseudouridine concentration. These results indicate that serum pseudouridine is a useful biochemical marker and that serum pseudouridine and alpha-fetoprotein in combination are considered to serve as complementary markers, for the diagnosis of hepatocellular carcinoma.